Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Monday

Key Points

• Lifecore Biomedical (NASDAQ:LFCR) is set to release its Q4 2025 earnings on August 25th, with analysts predicting a loss of ($0.09) per share and revenues of $35.36 million.
• The company's previous earnings report on August 7th showed a loss of ($0.10) per share, missing expectations, while revenues were $36.44 million, surpassing estimates.
• Wall Street analysts have a consensus "Hold" rating on Lifecore Biomedical with an average target price of $8.00, indicating cautious optimism amidst mixed performance.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Monday, August 25th. Analysts expect Lifecore Biomedical to post earnings of ($0.09) per share and revenue of $35.3630 million for the quarter. Lifecore Biomedical has set its FY 2026 guidance at EPS.Individuals can check the company's upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Thursday, August 7, 2025 at 4:30 PM ET.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). The company had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Up 5.3%

Shares of Lifecore Biomedical stock traded up $0.38 during midday trading on Friday, reaching $7.60. 119,681 shares of the company's stock traded hands, compared to its average volume of 116,304. The company has a market cap of $284.32 million, a price-to-earnings ratio of -5.80 and a beta of 0.65. The company's 50 day simple moving average is $7.58 and its 200 day simple moving average is $6.80. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.77 and a current ratio of 2.84. Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $8.85.

Insider Buying and Selling at Lifecore Biomedical

In related news, major shareholder Aron R. English sold 150,419 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the completion of the sale, the insider directly owned 264,180 shares of the company's stock, valued at $1,880,961.60. The trade was a 36.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 32.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lifecore Biomedical

Several large investors have recently bought and sold shares of LFCR. Invesco Ltd. acquired a new position in Lifecore Biomedical during the second quarter worth $3,081,000. Geode Capital Management LLC lifted its stake in shares of Lifecore Biomedical by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 775,493 shares of the company's stock worth $6,299,000 after buying an additional 24,995 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Lifecore Biomedical by 54.0% during the 2nd quarter. Rhumbline Advisers now owns 38,091 shares of the company's stock worth $309,000 after buying an additional 13,361 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Lifecore Biomedical by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 87,998 shares of the company's stock worth $620,000 after acquiring an additional 12,647 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in Lifecore Biomedical during the second quarter worth about $88,000. Institutional investors own 83.36% of the company's stock.

Analyst Ratings Changes

LFCR has been the topic of a number of research analyst reports. William Blair began coverage on shares of Lifecore Biomedical in a research note on Wednesday, May 21st. They issued an "outperform" rating on the stock. Wall Street Zen raised shares of Lifecore Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Lifecore Biomedical has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.